Protocol summary

Summary
The propose is to study the efficacy of Venlafaxine in the treatment of adult attention-deficit hyperactivity disorder (ADHD). Forty subjects between 18-45 years who clearly meet diagnostic criteria for adult ADHD, from parents and siblings of children with ADHD who are referred to child and adolescent psychiatric clinic of RAZI hospital will assign. Inclusion criteria: confirm of symptoms of ADHD in childhood & diagnosis of ADHD on clinical psychiatric interview. Exclusion criteria: any other psychiatric disorder and physical illness. This is a double blind randomized clinical trial study. Subjects receive either Venlafaxine or placebo randomly for 6 week. Venlafaxine will titrate up during the trial according to the following Schedule: week 1, 2; 75mg/day (once daily), week 3, 4 150mg/day (twice daily) and week 5, 6; 225mg/day (thrice daily). Patients will assess at baseline, 14, 28 and 42 days after the medication start with Adult Conner's questionnaires for assessing severity of symptoms of ADHD. Side effects will systematically record throughout the study and will assess using a checklist that comprises side effects by psychiatrist on days 14, 28 and 42.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT138808122660N1
Registration date: 2010-01-25, 1388/11/05
Registration timing: registered_while_recruiting

Last update:
Update count: 0
Registration date
2010-01-25, 1388/11/05
Registrant information
Name
Shahrokh Amiri Aziza Abad
Name of organization / entity
Tabriz university of medical sciences
Country
Iran (Islamic Republic of)
Phone
+98 41 1380 4486
Email address
amirish@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Vice chancellor for research of Tabriz University of Medical Sciences
Expected recruitment start date
2009-03-21, 1388/01/01
Expected recruitment end date
2010-03-21, 1389/01/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The efficacy of Venlafaxine in comparison with placebo in the treatment of adult with attention deficit hyperactivity disorder: A double blind randomized clinical trial
Public title
Use of Venlafaxine in the treatment of adult attention deficit hyperactivity disorder
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: 1. Age between 18-45 year 2. Having Adult attention deficit hyperactivity disorder (ADHD) according to the judgment of two psychiatrists 3. Confirm of ADHD symptoms at childhood period. Exclusion criteria: 1. Evidence of mental retardation ( IQ<70 based on clinical judgment ) 2. Other psychiatric comorbidity 3. Any significant chronic medical condition, including organic brain disorder and seizure 4. Current abuse or dependence on substance within 6 months 5. Pregnant and lactating women . 6. use any psychiatirc drugs in recent two weeks
Age
From 18 years old to 45 years old
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size: 40
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Vice Chancellor for research of Tabriz University of Medical Sciences
Street address
Gol-Gasht
City
Tabriz
Postal code
Approval date
2008-11-16, 1387/08/26
Ethics committee reference number
5/4/7306

Health conditions studied

1

Description of health condition studied
Adult ADHD (Attention-deficit hyperactivity disorder )
ICD-10 code
F90.9
ICD-10 code description
Hyperkinetic disorders

Primary outcomes

1

Description
Improvement in Attention-deficit symptoms
Timepoint
weeks 2, 4 and 6
Method of measurement
According to the self-report Conner's questionnaire

2

Description
Improvement in impulsivity
Timepoint
weeks 2, 4 and 6
Method of measurement
According to the Self-report Conner's questionnaire

3

Description
Improvement in hyperactivity symptoms
Timepoint
weeks 2, 4 and 6
Method of measurement
According to the Self-report Conner's questionnaire

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Venlafaxine; weeks 1, 2; 75mg/day (once daily), weeks 3, 4 150mg/day (twice daily) and weeks 5, 6; 225mg/day (thrice daily)
Category
Treatment - Drugs

2

Description
Control group: placebo
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Razi Psychiatric Hospital
Full name of responsible person
Dr.shahrokh Amiri , MD
Street address
El-Goli Baulevard
City
Tabriz

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Vice Chancellor for Research of Tabriz Univercity of Medical Sciences
Full name of responsible person
ِDr. Eteraf Oskouei
Street address
Golgasht
City
Tabriz
Grant name
بودجه پژوهشی
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice Chancellor for Research of Tabriz Univercity of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University Of Medical Sciences
Full name of responsible person
Shahrokh Amiri Azizabad
Position
Asisstant Professor Of Psychiatry
Other areas of specialty/work
Street address
Razi psychiatric Hospital, El Goli Boulevard
City
Tabriz
Postal code
Phone
+98 411380448690
Fax
+98 41 1380 3351
Email
Amirish@tbzmed.ac.ir , Sh_Amiri1348@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University Of Medical Sciences
Full name of responsible person
Shahrokh Amiri Azizabad
Position
Child & Adolescent psychiatrist
Other areas of specialty/work
Street address
Razi Psychiatric Hospital, El Goli Boulevard
City
Tabriz
Postal code
Phone
+98 411380448690
Fax
+98 41 1380 3351
Email
Sh_Amiri@tbzmed.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University Of Medical Sciences
Full name of responsible person
Soleiman Mohammadzadeh
Position
Psychiatry Residency
Other areas of specialty/work
Street address
Razi Psychiatric Hospital, El Goli Boulevard
City
Tabriz
Postal code
Phone
Fax
Email
seiywan@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty
Loading...